Smith v. Upper Chesapeake Medical Ctr.
A court ruling in Smith v. Upper Chesapeake Medical Ctr. allows practitioners to act beyond their licensed scope of practice, potentially affecting delegation and supervision requirements in med-spas.
Aforeworn detected this change in the Med-Spa & Aesthetics Clinics space on July 8, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Med-spa owners and medical directors, especially those delegating procedures like injectables and laser to non-physician practitioners. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Within 30 days to mitigate liability exposure.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Med-Spa & Aesthetics Clinics continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The ruling may expand permissible scope of practice for certain practitioners, but also increases legal risk if not properly documented and supervised.
Who it affects
Med-spa owners and medical directors, especially those delegating procedures like injectables and laser to non-physician practitioners.
What you must do
Review and update delegation protocols, supervision agreements, and scope-of-practice documents to align with this ruling and state regulations.
Deadline
Within 30 days to mitigate liability exposure.
Source: https://www.courtlistener.com/opinion/10852799/smith-v-upper-chesapeake-medical-ctr/
Never miss a change like this again
Aforeworn watches Med-Spa & Aesthetics Clinics around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Med-Spa & Aesthetics Clinics
- Beauty Lab and Laser v. Fowler
- Haugen / Norvell v. Oregon Health Authority
- Regulatory Considerations for Microneedling Products; Guidance for Industry and Food and Drug Administration Staff; Availability
- Hazardous Drugs: NIOSH List of Hazardous Drugs in Healthcare Settings, 2024 and Final Reevaluation Determinations for Liraglutide and Pertuzumab